Inclusion Criteria:

Male or female participant aged ≥ 18 years old

Participants with cytologically confirmed and documented treatment naïve, de novo or secondary AML defined by WHO 2016 classification (Arber, 2016). Secondary AML includes:

1. Previous myelodysplastic syndrome transformed
2. AML due to exposure to potentially leukemogenic therapies or agents (e.g. radiation therapy, alkylating agents, topoisomerase II inhibitors) with the primary malignancy in remission for at least 3 years

Participants not eligible for standard induction chemotherapy

Aged ≥ 75 years old

Or Age ≥18 years with at least one of the following comorbidities:

Clinically significant heart or lung comorbidities, as reflected by at least one of:

1. Lung diffusing capacity for carbon monoxide (DLCO) ≤65% of expected
2. Forced expiratory volume in 1 second (FEV1) ≤65% of expected
3. Other contraindication(s) to anthracycline therapy (must be documented)
4. Other comorbidity that the Investigator judges as incompatible with intensive remission induction chemotherapy, which must be documented
5. ECOG (Eastern Cooperative Oncology Group) performance status should be (criterion should be rechecked at inclusion visit) ECOG ≤ 2.
6. Written informed consent obtained prior any study-specific procedure as described in section 13.3 of the protocol.
7. Adequate renal and hepatic function
8. Circulating White Blood Cell Count (WBC count) < 25*109 G/L (with or without use of hydroxycarbamide/leukapheresis)
9. Serum potassium, serum calcium, serum phosphates, serum magnesium within normal limits with or without supplementation.

Exclusion Criteria:

1. Major surgery within 3 weeks prior to the first IMP administration, or participants who have not recovered from side effects of the surgery
2. Any radiotherapy within 3 weeks before the first IMP administration,
3. Allogenic stem cell transplant within 3 months before the first IMP administration and/or participants with active Graft-versus-host disease within 3 months before the first IMP administration and/or participants who still receive immunosuppressive treatment within 3 months before the first IMP administration and/or participant who receive donor lymphocyte infusion (DLI) within 3 months before the first IMP administration
4. Acute promyelocytic leukemia (APL, French-American-British M3 classification)
5. Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2016 for Acute Myeloid Leukemia
6. Treatment with hypomethylating agents (decitabine/azacitidine) or Venetoclax for AHD (antecedent hematologic disorders) in the 3 months prior to the first IMP intake